Breast CancerNCT07570368
Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer
A study testing Brief Acceptance and Commitment Therapy, Standard Counseling and Neoadjuvant Chemotherapy in people with Breast Cancer and Breast Neoplasm Female, run by Universitas Airlangga.
Trial summary
This clinical trial aims to learn whether a brief psychological therapy called Brief Acceptance and Commitment Therapy (Brief-ACT) can improve the effectiveness of neoadjuvant chemotherapy in patients with locally advanced breast cancer. Read more about this study
- Who is it for?
- Ages 40 to 65 years, women only
- Conditions the study is for
- Breast Cancer, Breast Neoplasm Female, Locally Advanced Breast Cancer (LABC)
- What is being tested?
- Brief Acceptance and Commitment Therapy, Standard Counseling and Neoadjuvant Chemotherapy
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- No sites listed yet
- Study dates
- 28 Apr 2026to Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Female patients aged 40-65 years
- Histologically confirmed locally advanced breast cancer
- Planned to undergo neoadjuvant chemotherapy
- ECOG performance status 0-2
- Able to provide informed consent
- Willing to participate in psychological intervention sessions
Who cannot join
- Severe psychological distress defined as Perceived Stress Scale (PSS-10) score ≥27
- Active infection or inflammatory disease
- Known autoimmune disease
- Cognitive impairment or psychiatric condition interfering with participation
- Concurrent participation in another interventional study
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Brief Acceptance and Commitment Therapy on Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer Through Modulation of Inflammatory and Angiogenic Biomarkers.
This clinical trial aims to learn whether a brief psychological therapy called Brief Acceptance and Commitment Therapy (Brief-ACT) can improve the effectiveness of neoadjuvant chemotherapy in patients with locally advanced breast cancer. It will also examine how this therapy affects stress levels and certain blood markers related to inflammation and tumor growth.
The main questions this study aims to answer are:
Read more
Does Brief-ACT improve the rate of pathological complete response (pCR) after chemotherapy? Does Brief-ACT reduce levels of inflammatory and angiogenic biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), neutrophil-to-lymphocyte ratio (NLR), and vascular endothelial growth factor (VEGF)? Does Brief-ACT reduce psychological stress in patients undergoing chemotherapy?
Researchers will compare patients who receive Brief-ACT in addition to standard chemotherapy with those who receive standard chemotherapy alone to see if there are differences in treatment response, stress levels, and biomarker levels.
Participants will:
Receive neoadjuvant chemotherapy according to standard treatment protocols Be assigned to receive Brief-ACT sessions or no additional psychological intervention Attend regular clinic visits for treatment and monitoring Provide blood samples at specific time points for laboratory analysis Complete questionnaires to assess psychological stress
Read the detailed description
Breast cancer patients with locally advanced disease frequently experience substantial psychological distress during treatment, which has been associated with adverse biological effects. Chronic psychological stress may activate neuroendocrine pathways, particularly the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased production of pro-inflammatory cytokines and angiogenic factors. These biological alterations, including elevated levels of interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and vascular endothelial growth factor (VEGF), are thought to contribute to tumor progression and resistance to chemotherapy.
Emerging evidence suggests that psychological interventions may influence these biological pathways. Acceptance and Commitment Therapy (ACT), particularly in its brief format (Brief-ACT), has been shown to improve psychological flexibility and reduce stress. However, its potential role in modulating inflammatory and angiogenic biomarkers and improving chemotherapy response in breast cancer patients remains insufficiently explored.
This study is designed as a randomized controlled trial to evaluate the effect of Brief-ACT on treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. The intervention is delivered alongside standard chemotherapy and focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, and value-based action.
In addition to evaluating clinical response, this study investigates the potential biological mechanisms underlying the effect of psychological intervention. Serial measurements of inflammatory and angiogenic biomarkers are performed to assess whether changes in psychological stress are associated with modulation of these pathways. This integrative approach aims to bridge psychological and biological domains in cancer treatment.
The findings of this study are expected to provide evidence on whether a structured psychological intervention can serve as an adjunctive strategy to improve chemotherapy outcomes through modulation of stress-related biological processes. If effective, this approach may support the integration of psychosocial care into standard oncological treatment to enhance both clinical and biological outcomes.
- Conditions
- Breast Cancer, Breast Neoplasm Female, Locally Advanced Breast Cancer (LABC), Locally Advanced Breast Cancer
- Being tested
- Brief Acceptance and Commitment Therapy, Standard Counseling, Neoadjuvant Chemotherapy
- Keywords
- breast cancer, Locally advanced breast cancer, brief acceptance and commitment therapy, acceptance and commitment therapy, neoadjuvant chemotherapy, clinical chemotherapy response, inflammatory biomarkers, angiogenic biomarkers, interleukin-6, neutrophil to lymphocyte ratio, vascular endothelial growth factor, psychological stress, psycho-oncology
- Medical subject headings
- Breast Neoplasms, Stress, Psychological
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Brief Acceptance and Commitment TherapyBehavioural
Brief Acceptance and Commitment Therapy (Brief-ACT) is a structured psychological intervention delivered during the course of neoadjuvant chemotherapy. The intervention focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, self-as-context, values clarification, and committed action. Sessions are delivered in a brief format tailored to the clinical setting and are integrated into routine oncology care during chemotherapy cycles.
Standard CounselingBehavioural
Standard counseling consists of routine supportive communication provided as part of standard clinical care during neoadjuvant chemotherapy. This includes general emotional support, basic health education, and non-directive discussion without the use of structured psychotherapeutic techniques such as Acceptance and Commitment Therapy. This intervention serves as an attention-control condition.
Neoadjuvant ChemotherapyDrug
Also called Neoadjuvant Chemotherapy (NACT), Neoadjuvant systemic therapy
Standard neoadjuvant chemotherapy regimen administered according to institutional protocols for locally advanced breast cancer.
| Study group | Role | What they receive |
|---|---|---|
| Brief-ACT + Neoadjuvant Chemotherapy | Experimental | Participants in this arm receive standard neoadjuvant chemotherapy in combination with Brief Acceptance and Commitment Therapy (Brief-ACT). The Brief-ACT intervention is delivered in structured sessions during the course of chemotherapy and focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, and value-based action. Receives: Behavioral: Brief Acceptance and Commitment Therapy; Drug: Neoadjuvant Chemotherapy |
| Standard Counseling + Neoadjuvant Chemotherapy | Active comparator | Participants in this arm receive standard neoadjuvant chemotherapy along with standard counseling provided as part of routine clinical care. The counseling serves as an attention-control condition to account for non-specific therapeutic effects, without incorporating structured Brief-ACT components. Receives: Behavioral: Standard Counseling; Drug: Neoadjuvant Chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Clinical response according to RECIST version 1.1
Clinical response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on radiologic tumor evaluation. Responses will be categorized as complete response, partial response, stable disease, or progressive disease according to RECIST 1.1 criteria.
Measured: At the end of cycle 3 (each cycle is 21 days), prior to surgery
Secondary outcomes (5)
Change in serum interleukin-6 (IL-6) level
Measured in pg/mL using enzyme-linked immunosorbent assay (ELISA)
Measured: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in neutrophil-to-lymphocyte ratio (NLR)
Calculated from complete blood count parameters
Measured: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in serum vascular endothelial growth factor A (VEGF-A) level
Measured in pg/mL using enzyme-linked immunosorbent assay (ELISA)
Measured: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in perceived stress level
Measured using the Perceived Stress Scale-10 (PSS-10)
Measured: Baseline (prior to intervention), and after completion of intervention, approximately 9 weeks after baseline measurement
Change in psychological flexibility measured by Acceptance and Action Questionnaire-II (AAQ-II)
Measured using the Acceptance and Action Questionnaire-II (AAQ-II), a self-reported instrument assessing psychological flexibility. Scores typically range from 7 to 49, with higher scores indicating greater psychological inflexibility (lower psychological flexibility)
Measured: Baseline (prior to initiation of study intervention) and after completion of intervention (approximately 6-9 weeks after baseline)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 May 2026
- Study start28 Apr 2026 (estimated)
- Primary completionJan 2027 (estimated)
- Study completionJan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study is a randomized, parallel-group clinical trial in which participants with locally advanced breast cancer are assigned to one of two groups: (1) standard neoadjuvant chemotherapy plus Brief Acceptance and Commitment Therapy (Brief-ACT), or (2) standard neoadjuvant chemotherapy alone. Randomization is performed to ensure balanced allocation between groups. The intervention is delivered concurrently with chemotherapy without crossover between groups.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 54 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Universitas Airlangga
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Vania Idelia Winantyo, Universitas Airlangga
- Investigators
- Asdi Wihandono, MD, Surgical Oncologist, Principal investigator, Universitas Airlangga
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07570368
- Sponsor's protocol ID
- 400.14.5.4/11991/102.9/2026
- Status last verified
- Apr 2026
- First submitted
- 23 Apr 2026
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Data sharing plans are currently under consideration. The study team intends to evaluate data sharing options following completion of the study and publication of the primary results, taking into account institutional policies, ethical considerations, and participant confidentiality.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Brief Acceptance and Commitment Therapy on Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer Through Modulation of Inflammatory and Angiogenic Biomarkers.
- ClinicalTrials.gov ID
- NCT07570368
- Acronym / sponsor ID
- 400.14.5.4/11991/102.9/2026
- Conditions
- Breast Cancer, Breast Neoplasm Female, Locally Advanced Breast Cancer (LABC), Locally Advanced Breast Cancer
- Keywords
- breast cancer, Locally advanced breast cancer, brief acceptance and commitment therapy, acceptance and commitment therapy, neoadjuvant chemotherapy, clinical chemotherapy response, inflammatory biomarkers, angiogenic biomarkers
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 54 participants (estimated)
- Lead sponsor
- Universitas AirlanggaUniversity, hospital or other
- Study start
- 28 Apr 2026 (estimated)
- Primary completion
- Jan 2027 (estimated)
- Study completion
- Jan 2027 (estimated)
- First posted
- 6 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial aims to learn whether a brief psychological therapy called Brief Acceptance and Commitment Therapy (Brief-ACT) can improve the effectiveness of neoadjuvant chemotherapy in patients with locally advanced breast cancer. It will also examine how this therapy affects stress levels and certain blood markers related to inflammation and tumor growth.
The main questions this study aims to answer are:
Does Brief-ACT improve the rate of pathological complete response (pCR) after chemotherapy? Does Brief-ACT reduce levels of inflammatory and angiogenic biomarkers such as C-reactive protein (CRP), interleukin-6 (IL-6), neutrophil-to-lymphocyte ratio (NLR), and vascular endothelial growth factor (VEGF)? Does Brief-ACT reduce psychological stress in patients undergoing chemotherapy?
Researchers will compare patients who receive Brief-ACT in addition to standard chemotherapy with those who receive standard chemotherapy alone to see if there are differences in treatment response, stress levels, and biomarker levels.
Participants will:
Receive neoadjuvant chemotherapy according to standard treatment protocols Be assigned to receive Brief-ACT sessions or no additional psychological intervention Attend regular clinic visits for treatment and monitoring Provide blood samples at specific time points for laboratory analysis Complete questionnaires to assess psychological stress
Detailed description
Breast cancer patients with locally advanced disease frequently experience substantial psychological distress during treatment, which has been associated with adverse biological effects. Chronic psychological stress may activate neuroendocrine pathways, particularly the hypothalamic-pituitary-adrenal (HPA) axis, leading to increased production of pro-inflammatory cytokines and angiogenic factors. These biological alterations, including elevated levels of interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), and vascular endothelial growth factor (VEGF), are thought to contribute to tumor progression and resistance to chemotherapy.
Emerging evidence suggests that psychological interventions may influence these biological pathways. Acceptance and Commitment Therapy (ACT), particularly in its brief format (Brief-ACT), has been shown to improve psychological flexibility and reduce stress. However, its potential role in modulating inflammatory and angiogenic biomarkers and improving chemotherapy response in breast cancer patients remains insufficiently explored.
This study is designed as a randomized controlled trial to evaluate the effect of Brief-ACT on treatment response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. The intervention is delivered alongside standard chemotherapy and focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, and value-based action.
In addition to evaluating clinical response, this study investigates the potential biological mechanisms underlying the effect of psychological intervention. Serial measurements of inflammatory and angiogenic biomarkers are performed to assess whether changes in psychological stress are associated with modulation of these pathways. This integrative approach aims to bridge psychological and biological domains in cancer treatment.
The findings of this study are expected to provide evidence on whether a structured psychological intervention can serve as an adjunctive strategy to improve chemotherapy outcomes through modulation of stress-related biological processes. If effective, this approach may support the integration of psychosocial care into standard oncological treatment to enhance both clinical and biological outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- This study is a randomized, parallel-group clinical trial in which participants with locally advanced breast cancer are assigned to one of two groups: (1) standard neoadjuvant chemotherapy plus Brief Acceptance and Commitment Therapy (Brief-ACT), or (2) standard neoadjuvant chemotherapy alone. Randomization is performed to ensure balanced allocation between groups. The intervention is delivered concurrently with chemotherapy without crossover between groups.
| Arm | Type | Receives |
|---|---|---|
| Brief-ACT + Neoadjuvant Chemotherapy | Experimental | Behavioral: Brief Acceptance and Commitment Therapy, Drug: Neoadjuvant ChemotherapyParticipants in this arm receive standard neoadjuvant chemotherapy in combination with Brief Acceptance and Commitment Therapy (Brief-ACT). The Brief-ACT intervention is delivered in structured sessions during the course of chemotherapy and focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, and value-based action. |
| Standard Counseling + Neoadjuvant Chemotherapy | Active comparator | Behavioral: Standard Counseling, Drug: Neoadjuvant ChemotherapyParticipants in this arm receive standard neoadjuvant chemotherapy along with standard counseling provided as part of routine clinical care. The counseling serves as an attention-control condition to account for non-specific therapeutic effects, without incorporating structured Brief-ACT components. |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Female patients aged 40-65 years
- Histologically confirmed locally advanced breast cancer
- Planned to undergo neoadjuvant chemotherapy
- ECOG performance status 0-2
- Able to provide informed consent
Key exclusion criteria (5 listed)
- Severe psychological distress defined as Perceived Stress Scale (PSS-10) score ≥27
- Active infection or inflammatory disease
- Known autoimmune disease
- Cognitive impairment or psychiatric condition interfering with participation
- Concurrent participation in another interventional study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Brief Acceptance and Commitment TherapyBrief Acceptance and Commitment Therapy (Brief-ACT) is a structured psychological intervention delivered during the course of neoadjuvant chemotherapy. The intervention focuses on enhancing psychological flexibility through core ACT processes, including acceptance, cognitive defusion, present-moment awareness, self-as-context, values clarification, and committed action. Sessions are delivered in a brief format tailored to the clinical setting and are integrated into routine oncology care during chemotherapy cycles. | Behavioural | Brief-ACT + Neoadjuvant Chemotherapy |
| Standard CounselingStandard counseling consists of routine supportive communication provided as part of standard clinical care during neoadjuvant chemotherapy. This includes general emotional support, basic health education, and non-directive discussion without the use of structured psychotherapeutic techniques such as Acceptance and Commitment Therapy. This intervention serves as an attention-control condition. | Behavioural | Standard Counseling + Neoadjuvant Chemotherapy |
| Neoadjuvant ChemotherapyAlso: Neoadjuvant Chemotherapy (NACT), Neoadjuvant systemic therapyStandard neoadjuvant chemotherapy regimen administered according to institutional protocols for locally advanced breast cancer. | Drug | Brief-ACT + Neoadjuvant Chemotherapy, Standard Counseling + Neoadjuvant Chemotherapy |
Primary outcome
Clinical response according to RECIST version 1.1
Time frame: At the end of cycle 3 (each cycle is 21 days), prior to surgery
Clinical response will be assessed using the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 based on radiologic tumor evaluation. Responses will be categorized as complete response, partial response, stable disease, or progressive disease according to RECIST 1.1 criteria.
5 secondary outcomes
Change in serum interleukin-6 (IL-6) level
Time frame: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in neutrophil-to-lymphocyte ratio (NLR)
Time frame: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in serum vascular endothelial growth factor A (VEGF-A) level
Time frame: Baseline (prior to initiation of chemotherapy) and after completion of cycle 3 chemotherapy (approximately 9 weeks, each cycle is 21 days)
Change in perceived stress level
Time frame: Baseline (prior to intervention), and after completion of intervention, approximately 9 weeks after baseline measurement
Change in psychological flexibility measured by Acceptance and Action Questionnaire-II (AAQ-II)
Time frame: Baseline (prior to initiation of study intervention) and after completion of intervention (approximately 6-9 weeks after baseline)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: Undecided. Data sharing plans are currently under consideration. The study team intends to evaluate data sharing options following completion of the study and publication of the primary results, taking into account institutional policies, ethical considerations, and participant confidentiality.
Related trials for Breast Cancer
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
RecruitingPhase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Not yet recruiting
Podcast-Based Psychosocial Support for Women Newly Diagnosed With Breast Cancer
Breast Cancer
Recruiting
A Study of Skipping Radiation Therapy in People With Breast Cancer
HER2-positive Breast Cancer, Breast Cancer
Active, not recruiting
Dance Study for Post-surgical Pain in Breast Cancer Survivors
Breast Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Asdi Wihandono, MD, Surgical Oncologist principal investigator
Universitas Airlangga
Questions about this trial
What is this clinical trial studying?
A study testing Brief Acceptance and Commitment Therapy, Standard Counseling and Neoadjuvant Chemotherapy in people with Breast Cancer and Breast Neoplasm Female, run by Universitas Airlangga.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Vania Idelia Winantyo, MD, General Surgeon (+6281906000050, vania.winantyo@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Clinical response according to RECIST version 1.1 (time frame: At the end of cycle 3 (each cycle is 21 days), prior to surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.